Chlamydia trachomatis infections and subfertility: Opportunities to translate host pathogen genomic data into public health

Public Health Genomics

Volumn 16, Issue 1-2, 2013, Pages 50-61

  Lal, J A ^a   Malogajski, J ^a   Verweij, S P ^b   De Boer, P ^c   Ambrosino, E ^a   Brand, A ^a   Ouburg, S ^b   Morre S A ^a,b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Ttopstart BV   (Netherlands)

Author keywords

Chlamydia trachomatis; Genomics; Host genetic markers; Learning Adapting Leveling model; Molecular diagnostics; Public health genomics; Stakeholders; Subfertility; Translation

Indexed keywords

CHEMOKINE RECEPTOR CCR5; GAMMA INTERFERON RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 6; MANNOSE BINDING LECTIN; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; PATTERN RECOGNITION RECEPTOR;

ARTICLE; CHLAMYDIASIS; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; ECTOPIC PREGNANCY; FEMALE; GENETIC DATABASE; GENETIC MARKER; HLA SYSTEM; HUMAN; IMMUNOASSAY; INFECTION SENSITIVITY; INFLAMMATION; INNATE IMMUNITY; LAPAROSCOPY; PELVIC INFLAMMATORY DISEASE; PREDICTIVE VALUE; PRIORITY JOURNAL; SUBFERTILITY; GENETIC ANALYSIS; GENETIC TRAIT; GENOMICS; PUBLIC HEALTH;

ALGORITHMS; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; CYTOKINES; FEMALE; GENETIC MARKERS; GENOMICS; HAPLOTYPES; HLA ANTIGENS; HUMANS; INFERTILITY, FEMALE; INFLAMMATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; PREGNANCY; PUBLIC HEALTH; TOLL-LIKE RECEPTORS; TRANSLATIONAL MEDICAL RESEARCH;

CHLAMYDIA; CHLAMYDIA TRACHOMATIS;

EID: 84876057643     PISSN: 16624246     EISSN: 16628063     Source Type: Journal    
DOI: 10.1159/000346207     Document Type: Article

References (73)

1. Manavi K: A review on infection with Chlamydia trachomatis. Best Pract Res Clin Obstet Gynaecol 2006; 20: 941-951.
2. Bébéar C, de Barbeyrac B: Genital Chlamydia trachomatis infections. Clin Microbiol Infect 2009; 15: 4-10.
3. Akande V, Turner C, Horner P, Horne A, Pacey A; British Fertility Society: Impact of Chlamydia trachomatis in the reproductive setting: British Fertility Society Guidelines for practice. Hum Fertil (Camb) 2010; 13: 115-125.
4. Land JA, van Bergen JEAM, Morré SA, Postma MJ: Epidemiology of Chlamydia trachomatis infection in women and the cost-effectiveness of screening. Hum Reprod Update 2010; 16: 189-204.
5. van Valkengoed IG, Morré SA, van den Brule AJ, Meijer CJLM, Bouter LM, van Eijk JT, Boeke AJ: Follow-up, treatment, and reinfection rates among asymptomatic Chlamydia trachomatis cases in general practice. Br J Gen Pract 2002; 52: 623-627.
6. Stamm WE: Diagnosis of Chlamydia trachomatis genitourinary infections. Ann Intern Med 1988; 108: 710-717.
7. Morré SA, Rozendaal L, van Valkengoed IG, Boeke AJ, van Voorst Vader PC, Schirm J, de Blok S, van Den Hoek JA, van Doornum GJ, Meijer CJ, van Den Brule AJ: Urogenital Chlamydia trachomatis serovars in men and women with a symptomatic or asymptomatic infection: an association with clinical manifestations? J Clin Microbiol 2000; 38: 2292-2296.
8. Brunham RC, Rey-Latino J: Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine. Nat Rev Immunol 2005; 5: 149-161.
9. Morré SA, Moes R, Van Valkengoed IG, Boeke JP, van Eijk JT, Meijer CJLM, Van den Brule AJ: Genotyping of Chlamydia trachomatis in urine specimens will facilitate large epidemiological studies. J Clin Microbiol 1998; 36: 3077-3078.
10. Molano M, Meijer CJLM, Morré SA, Pol R, van den Brule AJ: Combination of PCR targeting the VD2 of omp1 and reverse line blot analysis for typing of urogenital Chlamydia trachomatis serovars in cervical scrape specimens. J Clin Microbiol 2004; 42: 2935-2939.
11. den Hartog JE, Morré SA, Land JA: Chlamydia trachomatis -associated tubal factor subfertility: immunogenetic aspects and serological screening. Hum Reprod Update 2006; 12: 719-730.
12. Hill AV: Genetic susceptibility to malaria and other infectious diseases: from the MHC to the whole genome. Parasitology 1996; 112(suppl 112):S75-S84.
13. Frodsham AJ: Host genetics and the outcome of hepatitis B viral infection. Transpl Immunol 2005; 14: 183-186.
14. Smirnova I, Mann N, Dols A, Derkx HH, Hibberd ML, Levin M, Beutler B: Assay of locusspecific genetic load implicates rare Toll-like receptor 4 mutations in meningococcal susceptibility. Proc Natl Acad Sci USA 2003; 100: 6075-6080.
15. Bailey RL, Natividad-Sancho A, Fowler A, Peeling RW, Mabey DC, Whittle HC, Jepson AP: Host genetic contribution to the cellular immune response to Chlamydia trachomatis: heritability estimate from a Gambian twin study. Drugs Today (Barc) 2009; 45(suppl B):45-50.
16. den Hartog JE, Ouburg S, Land JA, Lyons JM, Ito JI, Peña AS, Morré SA: Do host genetic traits in the bacterial sensing system play a role in the development of Chlamydia trachomatis -associated tubal pathology in subfertile women? BMC Infect Dis 2006; 6: 122.
17. Morré SA, Karimi O, Ouburg S: Chlamydia trachomatis: identification of susceptibility markers for ocular and sexually transmitted infection by immunogenetics. FEMS Immunol Med Microbiol 2009; 55: 140-153.
18. Lal JA, Schultein den Bäumen T, Morré SA, Brand A: Public health and valorization of genome-based technologies: a new model. J Transl Med 2011; 9: 207.
19. Karimi O, Ouburg S, de Vries HJ, Peña AS, Pleijster J, Land JA, Morré SA: TLR2 haplotypes in the susceptibility to and severity of Chlamydia trachomatis infections in Dutch women. Drugs Today (Barc) 2009; 45(suppl B):67-74.
20. van der Paardt M; Crusius JBA; de Koning MHMT, Morré SA, van de Stadt RJ, Dijkmans BA, Peña AS, van der Horst-Bruinsma IE: No evidence for involvement of the Toll-like receptor 4. (TLR4) A896G and CD14- C260T polymorphisms in susceptibility to ankylosing spondylitis. Ann Rheum Dis 2005; 64: 235-238.
21. Laisk T, Peters M, Saare M, Haller-Kikkatalo K, Karro H, Salumets A: Association of CCR5, TLR2, TLR4 and MBL genetic variations with genital tract infections and tubal factor infertility. J Reprod Immunol 2010; 87: 74-81.
22. den Hartog JE, Lyons JM, Ouburg S, Fennema JS, de Vries HJ, Bruggeman CA, Ito JI, Peña AS, Land JA, Morré SA: TLR4 in Chlamydia trachomatis infections: knockout mice, STD patients and women with tubal factor subfertility. Drugs Today (Barc) 2009; 45(suppl B):75-82.
23. Taylor BD, Darville T, Ferrell RE, Kammerer CM, Ness RB, Haggerty CL: Variants in tolllike receptor 1 and 4 genes are associated with Chlamydia trachomatis among women with pelvic inflammatory disease. J Infect Dis 2012; 205: 603-609.
24. Ouburg S, Lyons JM, Land JA, den Hartog JE, Fennema JS, de Vries HJ, Bruggeman CA, Ito JI, Peña AS, Lundberg PS, Morré SA: TLR9 KO mice, haplotypes and CPG indices in Chlamydia trachomatis infection. Drugs Today (Barc) 2009; 45(suppl B):83-93.
25. Mueller A, Strange PG: The chemokine receptor, CCR5. Int J Biochem Cell Biol 2004; 36: 35-38.
26. Barr EL, Ouburg S, Igietseme JU, Morré SA, Okwandu E, Eko FO, Ifere G, Belay T, He Q, Lyn D, Nwankwo G, Lillard JW Jr, Black CM, Ananaba GA: Host inflammatory response and development of complications of Chlamydia trachomatis genital infection in CCR5-deficient mice and subfertile women with the CCR5Δ32 gene deletion. J Microbiol Immunol Infect 2005; 38: 244-254.
27. Turner MW: Mannose-binding lectin (MBL) in health and disease. Immunobiology 1998; 199: 327-339.
28. Swanson AF, Ezekowitz RA, Lee A, Kuo CC: Human mannose-binding protein inhibits infection of HeLa cells by Chlamydia trachomatis. Infect Immun 1998; 66: 1607-1612.
29. Laisk T, Peters M, Salumets A: Mannosebinding lectin genotypes: potential role in tubal damage and adverse IVF outcome. J Reprod Immunol 2011; 92: 62-67.
30. Kinnunen AH, Surcel HM, Lehtinen M, Karhukorpi J, Tiitinen A, Halttunen M, Bloigu A, Morrison RP, Karttunen R, Paavonen J: HLA DQ alleles and interleukin-10 polymorphism associated with Chlamydia trachomatis -related tubal factor infertility: a case-control study. Hum Reprod 2002; 17: 2073-2078.
31. Mei B, Luo Q, Du K, Huo Z, Wang F, Yu P: Association of MICA gene polymorphisms with Chlamydia trachomatis infection and related tubal pathology in infertile women. Hum Reprod 2009; 24: 3090-3095.
32. Ohman H, Tiitinen A, Halttunen M, Lehtinen M, Paavonen J, Surcel HM: Cytokine polymorphisms and severity of tubal damage in women with Chlamydia -associated infertility. J Infect Dis 2009; 199: 1353-1359.
33. Murillo LS, Land JA, Pleijster J, Bruggeman CA, Peña AS, Morré SA: Interleukin-1B (IL-1B) and interleukin-1 receptor antagonist (IL-1RN) gene polymorphisms are not associated with tubal pathology and Chlamydia trachomatis-related tubal factor subfertility. Hum Reprod 2003; 18: 2309-2314.
34. Hvid M, Baczynska A, Deleuran B, Fedder J, Knudsen HJ, Christiansen G, Birkelund S: Interleukin-1. is the initiator of Fallopian tube destruction during Chlamydia trachomatis infection. Cell Microbiol 2007; 9: 2795-2803.
35. Wang W, Stassen FR, Surcel HM, Ohman H, Tiitinen A, Paavonen J, de Vries HJ, Heijmans R, Pleijster J, Morré SA, Ouburg S: Analyses of polymorphisms in the inflammasome-associated NLRP3 and miRNA-146A genes in the susceptibility to and tubal pathology of Chlamydia trachomatis infection. Drugs Today (Barc) 2009; 45(suppl B):95-103.
36. Ohman H, Bailey R, Natividad A, Ragoussis J, Johnson LL, Tiitinen A, Halttunen M, Paavonen J, Surcel HM: Effect of IL12A and IL12B polymorphisms on the risk of Chlamydia trachomatis -induced tubal factor infertility and disease severity. Hum Reprod 2012; 27: 2217-2223.
37. Ohman H, Tiitinen A, Halttunen M, Paavonen J, Surcel HM: Cytokine gene polymorphism and Chlamydia trachomatis -specific immune responses. Hum Immunol 2011; 72: 278-282.
38. Ouburg S, Spaargaren J, den Hartog JE, Land JA, Fennema JS, Pleijster J, Peña AS, Morré SA; ICTI consortium: The CD14 functional gene polymorphism -260C>T is not involved in either the susceptibility to Chlamydia trachomatis infection or the development of tubal pathology. BMC Infect Dis 2005; 5: 114.
39. Atik B, Skwor TA, Kandel RP, Sharma B, Adhikari HK, Steiner L, Erlich H, Dean D: Identification of novel single nucleotide polymorphisms in inflammatory genes as risk factors associated with trachomatous trichiasis. PLoS One 2008; 3:e3600.
40. Morré SA, Spaargaren J, Ossewaarde JM, Land JA, Bax CJ, Dörr PJ, Oostvogel PM, Vanrompay D, Savelkoul PH, Pannekoek Y, van Bergen JE, Fennema HS, de Vries HJ, Crusius JB, Peña AS, Ito JI, Lyons JM: Description of the ICTI consortium: an integrated approach to the study of Chlamydia trachomatis infection. Drugs Today 2006; 42(suppl A):107-114.
41. Lyons JM, Ouburg S, Morré SA: An integrated approach to Chlamydia trachomatis infection: the ICTI Consortium, an update. Drugs Today 2009; 45(suppl B):15-23.
42. Morré SA, Ouburg S, Peña AS, Brand A: The EU FP6 EpiGenChlamydia Consortium: contribution of molecular epidemiology and host-pathogen genomics to understanding Chlamydia trachomatis -related disease. Drugs Today 2009; 45(suppl B):7-13.
43. Klint M, Fuxelius HH, Goldkuhl RR, Skarin H, Rutemark C, Andersson SG, Persson K, Herrmann B: High-resolution genotyping of Chlamydia trachomatis strains by multilocus sequence analysis. J Clin Microbiol 2007; 45: 1410-1414.
44. Pedersen LN, Herrmann B, Møller JK: Typing Chlamydia trachomatis: from egg yolk to nanotechnology. FEMS Immunol Med Microbiol 2009; 55: 120-130.
45. Evers JL: Female subfertility. Lancet 2002; 360: 151-159.
46. Broeze KA, Opmeer BC, Van Geloven N, Coppus SF, Collins JA, Den Hartog JE, Van der Linden PJ, Marianowski P, Ng EH, Van der Steeg JW, Steures P, Strandell A, Van der Veen F, Mol BW: Are patient characteristics associated with the accuracy of hysterosalpingography in diagnosing tubal pathology? An individual patient data meta-analysis. Hum Reprod Update 2011; 17: 293-300.
47. Akande VA, Hunt LP, Cahill DJ, Caul EO, Ford WC, Jenkins JM: Tubal damage in infertile women: prediction using Chlamydia serology. Hum Reprod 2003; 18: 1841-1847.
48. Tubal infertility: serologic relationship to past chlamydial and gonococcal infection. WHO Task Force on the Prevention and Management of Infertility. Sex Transm Dis 1995; 22: 71-77.
49. Jiang J, Karimi O, Ouburg S, Champion CI, Khurana A, Liu G, Freed A, Pleijster J, Rozengurt N, Land JA, Surcel HM, Tiitinen A, Paavonen J, Kronenberg M, Morré SA, Kelly KA: Interruption of CXCL13-CXCR5 axis increases upper genital tract pathology and activation of NKT cells following chlamydial genital infection. PLoS One 2012; 7:e47487.
50. Burke W, Khoury MJ, Stewart A, Zimmern RL: The path from genome-based research to population health: development of an international public health genomics network. Genet Med 2006; 8: 451-458.
51. Brand A: Public health genomics - public health goes personalized? Eur J Public Health 2011; 21: 2-3.
52. Lal JA, Schulte in den Bäumen T, Morré SA, Brand A: Public health and valorization of genome-based technologies: a new model. J Transl Med 2011; 9:e207.
53. Berwick DM: Disseminating innovations in health care. JAMA 2003; 289: 1969-1970.
54. Peng W: Trends in the biotech literature 2009. Nat Biotechnol 2010; 28: 887.
55. Snyder M, Cook-Deegan B: DNA Patent Database Statistics: 2010. DNA Patent Database. 2011.
56. Catalogue of Biotechnology Patents in the Mercosur. BIOTECHSUR. 2008. http://docs. biotecsur.org/informes/en/inventario/9-patentes- ms.pdf.
57. HM Government: Strength and Opportunity. The landscape of the medical technology, medical biotechnology and industrial biotechnology sectors in the UK. 2009; 11-12, 28, 34, 38, 40.
58. US Biotech Market Analysis: RNCOS Industry Research Solutions. 2010
59. Murtagh J, Foerster V: Managing Technology Diffusion-Discussion Paper. Canadian Agency for Drugs and Technologies in Health. 2009; 4: 7-8, 10.
60. Brand A, Brand H, Schulte in den Bäumen T: The impact of genetics and genomics on public health. Eur J Hum Genet 2008; 16: 5-13.
61. Rosenkötter N, Vondeling H, Blancquaert I, Mekel OCL, Kristensen FB, Brand A: The contribution of health technology assessment, health needs assessment, and health impact assessment to the assessment and translation of technologies in the field of public health genomics. Public Health Genomics 2010; 14: 43-52.
62. Battista RN: Expanding the scientific basis of health technology assessment: a research agenda for the next decade. Int J Technol Assess Health Care 2006; 22: 275-280.
63. Health Impact Assessment: Main concepts and suggested approach Gottenburg consensus paper. Brussels: European Center for Health Policy. 1999; 4.
64. Crow MM, Tucker C: The American research university system as America's de facto technology policy. Sci Public Policy 2001; 28: 2-9.
65. Haddow J, Palomaki G: ACCE: A model process for evaluating data on emerging genetic tests; in Khoury M, Little J, Burke W (eds): Human Genome Epidemiology. Oxford, Oxford University Press, 2004, pp 217-233.
66. Brand A: The future is being built today: facing the era of integrative genomics, personalgenome tests and personalized healthcare - a need for integrative minds? Eur J Hum Genet 2009; 17: 977-978.
67. Becla L, Lunshof JE, Gurwitz D, Schulte in den Bäumen T, Westerhoff HV, Lange BM, Brand A: Health technology assessment in the era of personalized health care. Int J Technol Assess Health Care 2011; 27: 118-126.
68. Beskow LM, Khoury MJ, Baker TG, Thrasher JF: The integration of Genomics into public health research, policy and practice in the United States. Community Genet 2001; 4: 2-11.
69. Oestreich T: The value of information Part 1-The Framework. Journal of Management Excellence: The Value of Information 2010; 9: 7-10. http://www.oracle.com/us/solutions/ business-intelligence/064068.pdf.
70. Brand A, Ambrosino E, Knoppers BM: Public Health Genomics journal: adjusting the agenda to future needs. Public Health Genomics 2011; 14: 125-126.
71. Hood L: A Doctor's Vision of the Future of Medicine. Newsweek, June 27, 2009.
72. Brand A, Lal JA; Public Health Genomics European Network: European Best Practice Guidelines for Quality Assurance, Provision and Use of Genome-based Information and Technologies - the 2012 Declaration of Rome. Drug Metabol Drug Interact 2012; 27: 177-182.
73. Lehrach H, Subrak R, Boyle P, Pasterk M, Zatloukal K, Müller H, Hubbard T, Brand A, Jameson D, Westerhoff HV: ITFoM - the IT future of medicine. Procedia Comput Sci 2011; 7: 26-29.